16 September 2026 editorial review · Item
Insulin glulisine (Apidra): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin glulisine (Apidra)
Scope and findings:
- US label confirms rapid human analogue,60min median serum peak,42min apparent half-life,meal window and pump compatibility contingent on pump IFU. EMA authorization retained. Pump occlusion comparative evidence and prices not newly reverified.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.